

# Antonino Ditto

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5117029/publications.pdf>

Version: 2024-02-01

177  
papers

4,575  
citations

101535

36  
h-index

155644

55  
g-index

179  
all docs

179  
docs citations

179  
times ranked

4471  
citing authors

#	ARTICLE	IF	CITATIONS
1	Uterine serous carcinoma: role of surgery, risk factors and oncologic outcomes. Experience of a tertiary center. <i>European Journal of Surgical Oncology</i> , 2022, 48, 268-274.	1.0	3
2	Validation of MiROvaR, a microRNA-based predictor of early relapse in early stage epithelial ovarian cancer as a new strategy to optimise patients' prognostic assessment. <i>European Journal of Cancer</i> , 2022, 161, 55-63.	2.8	3
3	The added value of SLN mapping with indocyanine green in low- and intermediate-risk endometrial cancer management: a systematic review and meta-analysis. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	2.2	11
4	Preoperative Conization and Risk of Recurrence in Patients Undergoing Laparoscopic Radical Hysterectomy for Early Stage Cervical Cancer: A Multicenter Study. <i>Journal of Minimally Invasive Gynecology</i> , 2021, 28, 117-123.	0.6	63
5	Spotlight on the role of human papillomavirus vaccines. <i>Gynecologic Oncology</i> , 2021, 160, 346-350.	1.4	14
6	Sentinel Node Mapping in Endometrial Cancer. <i>Journal of Investigative Surgery</i> , 2021, 34, 677-678.	1.3	0
7	The role of sentinel lymph node mapping in lower genital tract melanoma. <i>Minerva Ginecologica</i> , 2021, 72, 384-390.	0.8	2
8	Conization and lymph node evaluation as a fertility-sparing treatment for early stage cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 457-461.	2.5	10
9	Minimally invasive surgery in cervical cancer. <i>Minerva Obstetrics and Gynecology</i> , 2021, 73, .	1.0	3
10	Sentinel node mapping vs. sentinel node mapping plus back-up lymphadenectomy in high-risk endometrial cancer patients: Results from a multi-institutional study. <i>Gynecologic Oncology</i> , 2021, 161, 122-129.	1.4	31
11	Transmission of SARS-CoV-2 in Surgical Smoke during Laparoscopy: A Prospective, Proof-of-concept Study. <i>Journal of Minimally Invasive Gynecology</i> , 2021, 28, 1519-1525.	0.6	17
12	Fertility-Sparing Treatment of Patients with Endometrial Cancer: A Review of the Literature. <i>Journal of Clinical Medicine</i> , 2021, 10, 4784.	2.4	9
13	Minimally invasive surgery in cervical cancer. <i>Minerva Obstetrics and Gynecology</i> , 2021, 73, 145-148.	1.0	0
14	Investigating the Role of Minimally Invasive Radical Hysterectomy in Cervical Cancer. <i>Journal of Investigative Surgery</i> , 2020, 33, 387-388.	1.3	3
15	Lynch syndrome-related non-endometrioid endometrial cancer: analysis of outcomes. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 56-61.	2.5	5
16	Hysteroscopic versus cervical injection for sentinel node detection in endometrial cancer: A multicenter prospective randomised controlled trial from the Multicenter Italian Trials in Ovarian cancer (MITO) study group. <i>European Journal of Cancer</i> , 2020, 140, 1-10.	2.8	18
17	Assessing the Long-Term Role of Vaccination against HPV after Loop Electrosurgical Excision Procedure (LEEP): A Propensity-Score Matched Comparison. <i>Vaccines</i> , 2020, 8, 717.	4.4	28
18	Trends in prevalence in human papillomavirus types and their association with cervical dysplasia: an analysis on 15 138 women over 20 years. <i>European Journal of Cancer Prevention</i> , 2020, 29, 452-457.	1.3	1

#	ARTICLE	IF	CITATIONS
19	Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser Conization: A 5-year follow-up study. <i>Gynecologic Oncology</i> , 2020, 159, 636-641.	1.4	54
20	The Adoption of Viral Capsid-Derived Virus-Like Particles (VLPs) for Disease Prevention and Treatments. <i>Vaccines</i> , 2020, 8, 432.	4.4	12
21	The impact of HPV-specific infection in women diagnosed with atypical glandular cells: Results from the HPV-AGC study. <i>Pathology Research and Practice</i> , 2020, 216, 153184.	2.3	6
22	Ten-year follow-up study of long-term outcomes after conservative surgery for early-stage ovarian cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2020, 150, 169-176.	2.3	9
23	Survival outcomes in endometrial cancer patients having lymphadenectomy, sentinel node mapping followed by lymphadenectomy and sentinel node mapping alone: Long-term results of a propensity-matched analysis. <i>Gynecologic Oncology</i> , 2020, 158, 77-83.	1.4	33
24	Management of patients with ovarian cancer in the COVID-19 era. <i>Journal of Surgical Oncology</i> , 2020, 122, 122-123.	1.7	11
25	Cancer patients affected by COVID-19: Experience from Milan, Lombardy. <i>Gynecologic Oncology</i> , 2020, 158, 262-265.	1.4	36
26	Surgical oncology at the time of COVID-19 outbreak. <i>Journal of Surgical Oncology</i> , 2020, 122, 115-116.	1.7	8
27	Primary conization overcomes the risk of developing local recurrence following laparoscopic radical hysterectomy in early stage cervical cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2020, 151, 43-48.	2.3	14
28	Sentinel lymph node mapping in endometrial cancer: performance of hysteroscopic injection of tracers. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 332-338.	2.5	16
29	Adjuvant chemotherapy vs. observation in stage I clear cell ovarian carcinoma: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2020, 157, 293-298.	1.4	27
30	Patterns of recurrence after laparoscopic versus open abdominal radical hysterectomy in patients with cervical cancer: a propensity-matched analysis. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 987-992.	2.5	30
31	Age-specific predictors of cervical dysplasia recurrence after primary conization: analysis of 3,212 women. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e60.	2.2	12
32	Survival implication of lymphadenectomy in patients surgically treated for apparent early-stage uterine serous carcinoma. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e64.	2.2	30
33	Gynecologic oncology at the time of COVID-19 outbreak. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e72.	2.2	21
34	Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e92.	2.2	20
35	Neoadjuvant chemotherapy followed by interval debulking surgery for unresectable stage IVB Serous endometrial cancer. <i>Tumori</i> , 2019, 105, 92-97.	1.1	28
36	Cervical intraepithelial neoplasia in women who had vaccination against HPV. <i>International Journal of Gynecology and Obstetrics</i> , 2019, 147, 233-237.	2.3	8

#	ARTICLE	IF	CITATIONS
37	Advances in laparoscopic surgery for cervical cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 143, 76-80.	4.4	17
38	Predictive factors of recurrence in patients with early-stage epithelial ovarian cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2019, 145, 28-33.	2.3	8
39	RECIST 1.1 criteria predict recurrence-free survival in advanced ovarian cancer submitted to neoadjuvant chemotherapy. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2019, 237, 93-99.	1.1	14
40	Long-term results of fertility-sparing treatment for early-stage cervical cancer. <i>Gynecologic Oncology</i> , 2019, 154, 89-94.	1.4	29
41	Nomogram-based prediction of cervical dysplasia persistence/recurrence. <i>European Journal of Cancer Prevention</i> , 2019, 28, 435-440.	1.3	16
42	Minimally invasive surgery improves short-term outcomes of nerve-sparing radical hysterectomy in patients with cervical cancer: a propensity-matched analysis with open abdominal surgery. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e27.	2.2	28
43	Sentinel node mapping vs. lymphadenectomy in endometrial cancer: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2019, 153, 676-683.	1.4	105
44	The detrimental effect of adopting interval debulking surgery in advanced stage low-grade serous ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e4.	2.2	18
45	Treatment modalities for recurrent high-grade vaginal intraepithelial neoplasia. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e20.	2.2	14
46	Low-volume disease in endometrial cancer: The role of micrometastasis and isolated tumor cells. <i>Gynecologic Oncology</i> , 2019, 153, 670-675.	1.4	62
47	Impact of gene-specific germline pathogenic variants on presentation of endometrial cancer in Lynch syndrome. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 705-710.	2.5	7
48	Burden of lymphatic disease predicts efficacy of adjuvant radiation and chemotherapy in FIGO 2018 stage IIIc cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1355-1360.	2.5	13
49	Uterine Papillary Serous Carcinoma Arising in a Polyp. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 472-480.	1.3	10
50	Re: Concordance Between Intracervical and Fundal Injections for Sentinel Node Mapping in Patients With Endometrial Cancer? A Study Using Intracervical Radiotracer and Fundal Blue Dye Injections. <i>Clinical Nuclear Medicine</i> , 2019, 44, 848-849.	1.3	1
51	Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: a retrospective study. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e57.	2.2	52
52	New prophylactics human papilloma virus (HPV) vaccines against cervical cancer. <i>Journal of Obstetrics and Gynaecology</i> , 2019, 39, 1-10.	0.9	41
53	Regarding "When Less Is More: Minimally Invasive Surgery Compared to Laparotomy for Interval Debulking after Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer". <i>Journal of Minimally Invasive Gynecology</i> , 2019, 26, 573-574.	0.6	1
54	Predicting Factors for High-Grade Cervical Dysplasia in Women With Low-Grade Cervical Cytology and Nonvisible Squamocolumnar Junction. <i>Reproductive Sciences</i> , 2019, 26, 44-48.	2.5	2

#	ARTICLE	IF	CITATIONS
55	Artificial intelligence estimates the impact of human papillomavirus types in influencing the risk of cervical dysplasia recurrence: progress toward a more personalized approach. <i>European Journal of Cancer Prevention</i> , 2019, 28, 81-86.	1.3	12
56	Sentinel node mapping in endometrial cancer. <i>Translational Cancer Research</i> , 2019, 8, 2218-2219.	1.0	2
57	Role of bevacizumab in uterine leiomyosarcoma. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 126, 45-51.	4.4	4
58	The role of human papillomavirus vaccines in cervical cancer: Prevention and treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 122, 92-97.	4.4	53
59	Nerve-Sparing Approach Improves Outcomes of Patients Undergoing Minimally Invasive Radical Hysterectomy: A Systematic Review and Meta-Analysis. <i>Journal of Minimally Invasive Gynecology</i> , 2018, 25, 402-410.	0.6	21
60	Invasive Paget Disease of the Vulva. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 176-182.	2.5	25
61	Rectus Abdominis Myofascial Flap for Vaginal Reconstruction After Pelvic Exenteration. <i>Annals of Plastic Surgery</i> , 2018, 81, 576-583.	0.9	12
62	Surgical Efforts Might Mitigate Difference in Response to Neoadjuvant Chemotherapy in Stage III-IV Unresectable Ovarian Cancer: A Case-Control Multi-institutional Study. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1706-1713.	2.5	4
63	The addition of lymphadenectomy to secondary cytoreductive surgery in comparison with bulky node resection in patients with recurrent ovarian cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 143, 319-324.	2.3	5
64	Factors Predictive of 90-Day Morbidity, Readmission, and Costs in Patients Undergoing Pelvic Exenteration. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 975-982.	2.5	9
65	Potential impact of introducing a nonavalent HPV vaccination. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 142, 338-342.	2.3	8
66	Locally Advanced Cervical Cancer: Is a Trimodality Treatment a Safe and Effective Approach?. <i>Oncology</i> , 2018, 95, 239-245.	1.9	2
67	A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e40.	2.2	16
68	Artificial intelligence weights the importance of factors predicting complete cytoreduction at secondary cytoreductive surgery for recurrent ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e66.	2.2	28
69	LASER treatment for women with high-grade vaginal intraepithelial neoplasia: A propensity-matched analysis on the efficacy of ablative versus excisional procedures. <i>Lasers in Surgery and Medicine</i> , 2018, 50, 933-939.	2.1	25
70	Early diagnosis in endometrial cancer minimizes the impact of treatments. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 219, 631-632.	1.3	2
71	Oncologic effectiveness of nerve-sparing radical hysterectomy in cervical cancer. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e41.	2.2	12
72	Ovarian preservation in locally advanced cervical cancer undergoing neoadjuvant chemotherapy and radical surgery. <i>Minerva Obstetrics and Gynecology</i> , 2018, 70, 357-363.	1.0	1

#	ARTICLE	IF	CITATIONS
73	Human papillomavirus (HPV) persistence and HPV 31 predict the risk of recurrence in high-grade vaginal intraepithelial neoplasia. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 210, 157-165.	1.1	27
74	Minimally Invasive Surgical Staging in Early-stage Ovarian Carcinoma: A Systematic Review and Meta-analysis. <i>Journal of Minimally Invasive Gynecology</i> , 2017, 24, 552-562.	0.6	46
75	The association of pre-treatment HPV subtypes with recurrence of VIN. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 211, 37-41.	1.1	14
76	Investigational drugs for the treatment of cervical cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 389-402.	4.1	34
77	Accuracy of pre-operative hysteroscopic guided biopsy for predicting final pathology in uterine malignancies. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1275-1279.	2.5	11
78	Sentinel-lymph-node mapping in endometrial cancer. <i>Lancet Oncology</i> , The, 2017, 18, e234.	10.7	9
79	Assessing the Risk of Occult Cancer and 30-day Morbidity in Women Undergoing Risk-reducing Surgery: A Prospective Experience. <i>Journal of Minimally Invasive Gynecology</i> , 2017, 24, 837-842.	0.6	20
80	Impact of Blood Transfusions on Survival of Locally Advanced Cervical Cancer Patients Undergoing Neoadjuvant Chemotherapy Plus Radical Surgery. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 514-522.	2.5	15
81	Treatment of Genital Melanoma: Are We Ready for Innovative Therapies?. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1063-1063.	2.5	3
82	Impact of Surgical Route in Influencing the Risk of Lymphatic Complications After Ovarian Cancer Staging. <i>Journal of Minimally Invasive Gynecology</i> , 2017, 24, 739-746.	0.6	19
83	Retrospective study of the influence of <scp>HPV</scp> persistence on outcomes among women with high-risk <scp>HPV</scp> infections and negative cytology. <i>International Journal of Gynecology and Obstetrics</i> , 2017, 138, 62-68.	2.3	16
84	The Impact of Number of Cycles of Neoadjuvant Chemotherapy on Survival of Patients Undergoing Interval Debulking Surgery for Stage III-IV Unresectable Ovarian Cancer: Results From a Multi-Institutional Study. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1856-1862.	2.5	42
85	Introducing nerve-sparing approach during minimally invasive radical hysterectomy for locally-advanced cervical cancer: A multi-institutional experience. <i>European Journal of Surgical Oncology</i> , 2017, 43, 2150-2156.	1.0	22
86	Sentinel node mapping in endometrial cancer following Hysteroscopic injection of tracers: A single center evaluation over 200 cases. <i>Gynecologic Oncology</i> , 2017, 146, 525-530.	1.4	30
87	Assessing the risk of pelvic and para-aortic nodal involvement in apparent early-stage ovarian cancer: A predictors- and nomogram-based analyses. <i>Gynecologic Oncology</i> , 2017, 147, 61-65.	1.4	39
88	Interpregnancy Interval and Adverse Pregnancy Outcomes: An Analysis of Successive Pregnancies. <i>Obstetrics and Gynecology</i> , 2017, 130, 464-465.	2.4	2
89	Implementation of Extensive Cytoreduction Resulted in Improved Survival Outcomes for Patients with Newly Diagnosed Advanced-Stage Ovarian, Tubal, and Peritoneal Cancers. <i>Annals of Surgical Oncology</i> , 2017, 24, 3396-3405.	1.5	11
90	Pharmacokinetic drug evaluation of pazopanib for the treatment of uterine leiomyosarcomas. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 881-889.	3.3	8

#	ARTICLE	IF	CITATIONS
91	Regarding "The Role of Routine Peritoneal and Omental Biopsies at Risk-reducing Salpingo-oophorectomy". Journal of Minimally Invasive Gynecology, 2017, 24, 1243-1244.	0.6	0
92	Minimally Invasive Surgical Staging for Ovarian Carcinoma: A Propensity-Matched Comparison With Traditional Open Surgery. Journal of Minimally Invasive Gynecology, 2017, 24, 98-102.	0.6	32
93	Laparoscopic Sentinel Node Mapping in Endometrial Cancer After Hysteroscopic Injection of Indocyanine Green. Journal of Minimally Invasive Gynecology, 2017, 24, 89-93.	0.6	29
94	Chemotherapy-related leukopenia as a biomarker predicting survival outcomes in locally advanced cervical cancer. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 208, 41-45.	1.1	12
95	3D Vision Improves Outcomes in Early Cervical Cancer Treated with Laparoscopic Type B Radical Hysterectomy and Pelvic Lymphadenectomy. Tumori, 2017, 103, 76-80.	1.1	9
96	Bulky Mesonephric Adenocarcinoma of the Uterine Cervix Treated with Neoadjuvant Chemotherapy and Radical Surgery: Report of the First Case. Tumori, 2016, 102, S82-S83.	1.1	4
97	Morcellation of apparent benign uterine myoma: assessing risk to benefit ratio. Journal of Gynecologic Oncology, 2016, 27, e37.	2.2	5
98	Sentinel lymph node detection in endometrial cancer: does injection site make a difference?. Journal of Gynecologic Oncology, 2016, 27, e23.	2.2	8
99	Incorporating 3D Laparoscopy for the Management of Locally Advanced Cervical Cancer: A Comparison with Open Surgery. Tumori, 2016, 102, 393-397.	1.1	10
100	Surgical Management and Prognostic Factors of Vulvovaginal Melanoma. Journal of Lower Genital Tract Disease, 2016, 20, e24-e29.	1.9	33
101	Laparoscopic fertility-sparing surgery for early ovarian epithelial cancer: A multi-institutional experience. Gynecologic Oncology, 2016, 141, 461-465.	1.4	48
102	Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: A systematic review and meta-analysis. Gynecologic Oncology, 2016, 143, 443-447.	1.4	44
103	Is aortic lymphadenectomy indicated in locally advanced cervical cancer after neoadjuvant chemotherapy followed by radical surgery? A retrospective study on 261 women. European Journal of Surgical Oncology, 2016, 42, 1512-1518.	1.0	0
104	FDG-PET/CT to Predict Optimal Primary Cytoreductive Surgery in Patients with Advanced Ovarian Cancer: Preliminary Results. Tumori, 2016, 102, 103-107.	1.1	26
105	Morcellation of undiagnosed uterine sarcoma: A critical review. Critical Reviews in Oncology/Hematology, 2016, 98, 302-308.	4.4	27
106	Morcellator's Port-site Metastasis of a Uterine Smooth Muscle Tumor of Uncertain Malignant Potential After Minimally Invasive Myomectomy. Journal of Minimally Invasive Gynecology, 2016, 23, 647-649.	0.6	17
107	Surgical Techniques for Diaphragmatic Resection During Cytoreduction in Advanced or Recurrent Ovarian Carcinoma. International Journal of Gynecological Cancer, 2016, 26, 371-380.	2.5	15
108	Extraperitoneal Robotic-Assisted Para-Aortic Lymphadenectomy in Gynecologic Cancer Staging: Current Evidence. Journal of Minimally Invasive Gynecology, 2016, 23, 489-496.	0.6	7



#	ARTICLE	IF	CITATIONS
109	Risk-reducing surgery on the uterine adnexa: timing and type of surgical treatment, and pathology report. <i>Minerva Ginecologica</i> , 2016, 68, 536-43.	0.8	3
110	Peritoneal cytology as prognostic factor in cervical cancer. <i>Diagnostic Cytopathology</i> , 2015, 43, 705-709.	1.0	6
111	A critical assessment on the role of sentinel node mapping in endometrial cancer. <i>Journal of Gynecologic Oncology</i> , 2015, 26, 252.	2.2	14
112	Fertility-sparing surgery in high-risk ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2015, 26, 350.	2.2	9
113	Long-term safety of fertility sparing surgery in early stage ovarian cancer: Comparison to standard radical surgical procedures. <i>Gynecologic Oncology</i> , 2015, 138, 78-82.	1.4	61
114	How often parametrial involvement leads to post-operative adjuvant treatment in locally advanced cervical cancer after neoadjuvant chemotherapy and type C radical hysterectomy?. <i>European Journal of Surgical Oncology</i> , 2015, 41, 1089-1096.	1.0	21
115	Sentinel Node Mapping Using Hysteroscopic Injection of Indocyanine Green and Laparoscopic Near-Infrared Fluorescence Imaging in Endometrial Cancer Staging. <i>Journal of Minimally Invasive Gynecology</i> , 2015, 22, 132-133.	0.6	32
116	Implementation of laparoscopic approach for type B radical hysterectomy: A comparison with open surgical operations. <i>European Journal of Surgical Oncology</i> , 2015, 41, 34-39.	1.0	78
117	Incidence of port-site hernia following robotic-assisted sacrocolpopexy. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015, 194, 249-250.	1.1	1
118	Surgical Treatment of Recurrent Endometrial Cancer: Time for a Paradigm Shift. <i>Annals of Surgical Oncology</i> , 2015, 22, 4204-4210.	1.5	41
119	Fertility-Sparing Surgery in Early-Stage Cervical Cancer Patients. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 493-497.	2.5	31
120	When Does Neoadjuvant Chemotherapy Really Avoid Radiotherapy? Clinical Predictors of Adjuvant Radiotherapy in Cervical Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 944-951.	1.5	13
121	Pneumoperitoneum pressures during pelvic laparoscopic surgery: a systematic review and meta-analysis. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015, 195, 1-6.	1.1	8
122	Treatment of Early Ovarian Cancer. , 2015, , 419-427.		0
123	Fertility sparing surgery in early stage epithelial ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2014, 25, 320.	2.2	53
124	Role of paclitaxel and cisplatin as the neoadjuvant treatment for locally advanced squamous cell carcinoma of the vulva. <i>Journal of Gynecologic Oncology</i> , 2014, 25, 22.	2.2	29
125	High-Risk Borderline Ovarian Tumors: Analysis of Clinicopathological Features and Prognostic Impact of Different Follow-Up Strategies. <i>Oncology</i> , 2014, 87, 183-192.	1.9	5
126	Carboplatin-Paclitaxel Versus Cisplatin-Ifosfamide in the Treatment of Uterine Carcinosarcoma: A Retrospective Cohort Study. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1256-1261.	2.5	12



#	ARTICLE	IF	CITATIONS
127	Phase II Trial on Cisplatin-Adriamycin-Paclitaxel Combination as Neoadjuvant Chemotherapy for Locally Advanced Cervical Adenocarcinoma. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 729-734.	2.5	26
128	Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: A multicenter study. <i>European Journal of Surgical Oncology</i> , 2014, 40, 891-898.	1.0	40
129	Class II versus Class III radical hysterectomy in early cervical cancer: An observational study in a tertiary center. <i>European Journal of Surgical Oncology</i> , 2014, 40, 883-890.	1.0	14
130	Management of endometrial cancer in Italy: A national survey endorsed by the Italian Society of Gynecologic Oncology. <i>International Journal of Surgery</i> , 2014, 12, 1038-1044.	2.7	15
131	Laparoscopic Versus Open Radical Hysterectomy for Stage IB2â€“IIB Cervical Cancer in the Setting of Neoadjuvant Chemotherapy: A Multi-institutional Cohort Study. <i>Annals of Surgical Oncology</i> , 2013, 20, 2007-2015.	1.5	38
132	Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: Results of a phase II multicentric study. <i>European Journal of Cancer</i> , 2013, 49, 1065-1072.	2.8	26
133	The Different Impact of BRCA Mutations on the Survival of Epithelial Ovarian Cancer Patients: A Retrospective Single-Center Experience. <i>Oncology</i> , 2013, 85, 122-127.	1.9	10
134	The Role of Lymphadenectomy in Cervical Cancer Patients: The Significance of the Number and the Status of Lymph Nodes Removed in 526 Cases Treated in a Single Institution. <i>Annals of Surgical Oncology</i> , 2013, 20, 3948-3954.	1.5	55
135	Photodynamic therapy with M-ALA as non surgical treatment option in patients with primary extramammary Paget's disease. <i>Gynecologic Oncology</i> , 2013, 130, 90-94.	1.4	44
136	Advanced ovarian cancer: Omental bursa, lesser omentum, celiac, portal and triad nodes spread as cause of inaccurate evaluation of residual tumor. <i>Gynecologic Oncology</i> , 2013, 129, 92-96.	1.4	34
137	Embryonal Rhabdomyosarcoma of the Uterine Cervix in Adults. <i>Journal of Lower Genital Tract Disease</i> , 2013, 17, e12-e17.	1.9	15
138	Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFκB pathway in advanced-stage epithelial ovarian cancer. <i>Oncogene</i> , 2012, 31, 4139-4149.	5.9	108
139	Diagnostic accuracy of sentinel node in endometrial cancer by using hysteroscopic injection of radiolabeled tracer. <i>Gynecologic Oncology</i> , 2012, 126, 419-423.	1.4	68
140	Systematic Para-aortic and Pelvic Lymphadenectomy in Early Stage Epithelial Ovarian Cancer: A Prospective Study. <i>Annals of Surgical Oncology</i> , 2012, 19, 3849-3855.	1.5	61
141	Class III Nerve-sparing Radical Hysterectomy Versus Standard Class III Radical Hysterectomy: An Observational Study. <i>Annals of Surgical Oncology</i> , 2011, 18, 3469-3478.	1.5	45
142	Class III NSRH: Oncological outcome in 170 cervical cancer patients. <i>Gynecologic Oncology</i> , 2010, 119, 192-197.	1.4	18
143	A phase 2 multicenter study of irinotecan and cisplatin as neoadjuvant treatment in patients with locally advanced cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 1569-75.	2.5	15
144	c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome. <i>Endocrine-Related Cancer</i> , 2009, 16, 443-453.	3.1	19

#	ARTICLE	IF	CITATIONS
145	Neoadjuvant Chemoradiation Followed by Radical Hysterectomy in FIGO Stage IIIB Cervical Cancer: Feasibility, Complications, and Clinical Outcome. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1119-1124.	2.5	29
146	Nerve-Sparing Radical Vaginectomy. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 794-797.	2.5	3
147	Quality of Life and Sexual, Bladder, and Intestinal Dysfunctions After Class III Nerve-Sparing and Class II Radical Hysterectomies. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 953-957.	2.5	52
148	Hysteroscopy in endometrial cancer: new methods to evaluate transtubal leakage of saline distension medium. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 198, 214.e1-214.e4.	1.3	18
149	Subcellular Localization of Activated Leukocyte Cell Adhesion Molecule Is a Molecular Predictor of Survival in Ovarian Carcinoma Patients. <i>Clinical Cancer Research</i> , 2008, 14, 1726-1733.	7.0	83
150	Primary Uterine Cervix Melanoma Resembling Malignant Peripheral Nerve Sheath Tumor: A Case Report. <i>International Journal of Gynecological Pathology</i> , 2008, 27, 596-600.	1.4	19
151	Incidental Diagnosis of Primary Vaginal Adenocarcinoma of Intestinal Type. <i>International Journal of Gynecological Pathology</i> , 2007, 26, 490-493.	1.4	19
152	Nerve-sparing radical hysterectomy in cervical cancer: Evolution of concepts. <i>Gynecologic Oncology</i> , 2007, 107, S119-S121.	1.4	31
153	Surgical Treatment in FIGO Stage I Cervical Cancer: Evolution of Concepts. <i>Current Women's Health Reviews</i> , 2007, 3, 129-137.	0.2	0
154	Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan. <i>European Journal of Surgical Oncology</i> , 2006, 32, 671-675.	1.0	105
155	Type II versus Type III Nerve-sparing Radical hysterectomy: Comparison of lower urinary tract dysfunctions. <i>Gynecologic Oncology</i> , 2006, 102, 256-262.	1.4	81
156	Clinical and pathological prognostic factors in squamous cell carcinoma of the vulva. <i>Gynecologic Oncology</i> , 2006, 102, 333-337.	1.4	94
157	Photodynamic therapy using a methyl ester of 5-aminolevulinic acid in recurrent Paget's disease of the vulva: A pilot study. <i>Gynecologic Oncology</i> , 2006, 103, 581-586.	1.4	80
158	Lymphatic mapping for endometrial cancer: Is hysteroscopic injection a safe technique for sentinel lymph node biopsy?. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 193, 1880-1881.	1.3	6
159	Prognostic factors in microinvasive cervical squamous cell cancer: long-term results. <i>International Journal of Gynecological Cancer</i> , 2005, 15, 88-93.	2.5	21
160	p53 Gene Status and Response to Topotecan-Containing Chemotherapy in Advanced Ovarian Carcinoma. <i>Oncology</i> , 2005, 69, 154-158.	1.9	5
161	Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. <i>Oncogene</i> , 2004, 23, 8171-8183.	5.9	75
162	Nerve-sparing radical hysterectomy: a surgical technique for preserving the autonomic hypogastric nerve. <i>Gynecologic Oncology</i> , 2004, 93, 307-314.	1.4	119

#	ARTICLE	IF	CITATIONS
163	Hysteroscopic injection of tracers in sentinel node detection of endometrial cancer: a feasibility study. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 191, 435-439.	1.3	77
164	Gemcitabine Combined with Oxaliplatin (GEMOX) as Second-Line Chemotherapy in Patients with Advanced Ovarian Cancer Refractory or Resistant to Platinum and Taxane. <i>Oncology</i> , 2004, 67, 376-381.	1.9	28
165	Microinvasive squamous cell cervical carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 48, 251-261.	4.4	19
166	False-negative sentinel node in patients with vulvar cancer: A case study. <i>International Journal of Gynecological Cancer</i> , 2003, 13, 361-363.	2.5	22
167	Nerve-sparing radical hysterectomy: a pilot study. <i>Tumori</i> , 2003, 89, 497-501.	1.1	7
168	Surgical Treatment of Gastric Metastases from Cutaneous Melanoma: Experience of the National Cancer Institute of Milan. <i>Tumori</i> , 2001, 87, 229-231.	1.1	6
169	Bone Mineral Density and Biochemical Markers of Bone Turnover in Peri- and Postmenopausal Women. <i>Calcified Tissue International</i> , 2000, 66, 263-267.	3.1	34
170	Prognostic Indicators in Melanoma of the Vulva. <i>Annals of Surgical Oncology</i> , 2000, 7, 738-742.	1.5	58
171	Association between Cutaneous Melanoma and Neurofibromatosis Type 1: Analysis of Three Clinical Cases and Review of the Literature. <i>Tumori</i> , 2000, 86, 70-74.	1.1	16
172	Low-dose danazol after combined surgical and medical therapy reduces the incidence of pelvic pain in women with moderate and severe endometriosis. <i>Human Reproduction</i> , 1999, 14, 2371-2374.	0.9	46
173	Comparison of two malignancy risk indices based on serum CA125, ultrasound score and menopausal status in the diagnosis of ovarian masses. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1999, 106, 524-527.	2.3	76
174	Total abdominal hysterectomy: a randomized study comparing two techniques. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 1999, 85, 141-145.	1.1	3
175	Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 1999, 72, 282-285.	1.0	254
176	Vitamin B12 levels in pregnancy influence erythropoietin response to anemia. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 1998, 80, 63-66.	1.1	2
177	Surgical treatment of ovarian dermoid cysts. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 1998, 81, 47-50.	1.1	35